The landscape of genetic medicine took a significant stride forward as pharmaceutical giant Eli Lilly and Company joined forces with…
Read More
Japan Ministry of Health Labour and Welfare Approves Viatris Wakix Pitolisant for Excessive Daytime Sleepiness and Narcolepsy
Viatris has secured a major regulatory milestone in East Asia as Japan’s Ministry of Health, Labour and Welfare (MHLW) officially…
Read More
Cellares and GenomeFrontier Therapeutics Partner to Automate Virus-Free CAR-T Cell Therapy Manufacturing on the Cell Shuttle Platform
The global cell therapy landscape is undergoing a profound structural shift as biotechnology innovators increasingly look toward end-to-end automation to…
Read More
Novo Partners with Anthropic to Harness Claude AI in Ambitious R&D Overhaul
Pharmaceutical giant Novo has announced a strategic partnership with artificial intelligence pioneer Anthropic, leveraging the tech company’s advanced AI assistant,…
Read More
Gilead Sciences and PAHO Partner to Expand Twice-Yearly Lenacapavir PrEP Access Across Latin America and the Caribbean
The landscape of global human immunodeficiency virus (HIV) prevention is undergoing a critical transformation following a landmark agreement between biopharmaceutical…
Read More
Looking beyond short-term turmoil, Syngene is investing for the future – Pharmaceutical Technology
The global contract research, development, and manufacturing organization (CDMO) sector is undergoing a profound structural evolution, driven by shifting supply…
Read More
Sling Therapeutics Secures $123M in Series C Financing to Advance Pivotal Phase III Trial of First-in-Class Oral TED Treatment
Sling Therapeutics has closed a significant $123 million Series C financing round, directing the capital toward the pivotal late-stage clinical…
Read More
Evaluating ERS 2026 Insights on Biologic Therapies for Obesity-Driven Asthma Phenotypes
The intersection of metabolic disease and respiratory medicine has emerged as one of the most critical frontiers in modern clinical…
Read More
GSK Expands Oncology Footprint with Chimagen Trispecific T-Cell Engager Deal for Multiple Myeloma
British pharmaceutical giant GSK has significantly deepened its footprint in the oncology sector by securing the global rights to an…
Read More
The Paradigm Shift in Healthcare: How Cell and Gene Therapies Are Redefining the Treatment of Rare Diseases
Rare diseases have long presented one of the most stubborn and heartbreaking frontiers in modern medicine. Historically characterized by profound…
Read More
